A NEW ERA OF VACCINES

The Novavax COVID-19 Vaccine, Adjuvanted is
now available in the U.S. under Emergency Use
Authorization for primary vaccination for individuals 12+
See conditions of use

Latest press release on vaccine candidates

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

2 billion

doses per year
at full capacity

10+ years

of nanoparticle
vaccine development

1,500+

employees
worldwide

6

areas of
research

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that
NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Novavax first quarter 2022 financial results

Browse the calendar and sign up to view investor-related events and announcements. Webcasts and presentations that have been archived are also available by viewing historical event details.

Latest quarterly earnings
Latest investor presentation
2021 annual report
NASDAQ:NVAX
Loading data...

Explore current opportunities in:

Insights

Why do we need vaccine booster injections?

Science & technology

Our pipeline—creating tomorrow's vaccines today

Who we are

Novavax is powered by global collaborations